An interventional study of Immunocal in Mild Cognitive Impairment (MCI), sponsored by Immunotec Inc.. Status unknown at 1 site in Canada. Open to participants aged 55 Years to 85 Years. Per ClinicalTrials.gov, last updated 2021-02-10.
Sponsored by Immunotec Inc. · Not applicable, Interventional, and Health services research
Among 223 studies in Cognitive Dysfunction with a site in Canada — 60 open to participants now, 79 under way, 7 of them phase 3. Cognitive Dysfunction · Canada.
Among the 223 studies in Cognitive Dysfunction with a site in Canada, this one is the 133rd largest by planned enrollment of the 170 interventional ones that give a count, is one of 20 that started in 2018, is one of 115 with no phase, and was the 80th registered.
3,872 studies on the registry are indexed under Cognitive Dysfunction; 1,119 are open to participants now.
Browse Cognitive Dysfunction studies →60 of the 223 studies in Cognitive Dysfunction with a site in Canada are open now. Recruiting first, the newest first:
Posit Science Corporation · Sites in Canada
Laval University · Sites in Canada
Qanatpharma AG · Sites in Canada
University of British Columbia · Sites in Canada
Ottawa Hospital Research Institute · Sites in Canada
A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →
Of the 750 Cognitive Dysfunction studies recruiting now, 362 (48%) set no upper age limit and 143 (19%) stop at 75 or younger; 46 take children under 18; 259 take healthy volunteers.
This study: 55 Years to 85 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
223 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 29 · Phase 3 21 · Phase 4 3
First in 1999; this study’s year is marked. 20 started in 2018.
This study's planned enrollment of 25 is below the median of 64 across 2,794 interventional studies indexed under Cognitive Dysfunction.
Median enrollment 62 across the 170 interventional studies, 353 across the 52 observational. Of the 121 that completed or were terminated, 17 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 223 have an industry lead sponsor. The 10 most frequent:
Immunotec Inc. is the lead sponsor of 3 studies on the registry; none are open to participants now.
Immunotec Inc. has 1 study filed under Cognitive Dysfunction — fewer than ten, so there is no comparison to draw.
24 of the studies in Cognitive Dysfunction with a site in Canada that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03887455Phase 3Eisai Inc.A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease | 2026-12-31 |
| NCT05230758Phase 3Donald MabbottEffect of Metformin on Behaviour and the Brain in Children Treated for a Brain Tumour | 2027-11-30 |
| NCT06529744University Health Network, TorontoImproving Prognostic Confidence in Neurodegenerative Diseases Causing Dementia Using Peripheral Biomarkers and Integrative Modeling | 2026-11 |
| NCT04335994Sunnybrook Health Sciences CentreENhancing Outcomes in Cognitive Impairment Through Use of Home Sleep ApNea Testing | 2026-12 |
| NCT06783283Centre for Addiction and Mental HealthTACS to Engage Theta-Gamma Coupling and Enhance Working Memory in Patients With MCI (tACS-MCI) | 2026-12 |
Among the 223 studies in Cognitive Dysfunction with a site in Canada, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Alzheimer disease (AD) is a dementing illness characterized by progressive neuronal degeneration, gliosis, and the accumulation of intracellular inclusions and extracellular deposits of amyloid in discrete regions of the basal forebrain, hippocampus, and the association cortices. Mild cognitive impairment (MCI) refers to individuals with cognitive impairment (often memory loss) that fails to meet clinical criteria for AD or another dementing illness.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
This study is recruiting Mild Cognitive Impaired (MCI) patients from the Memory Clinic of the Jewish General Hospital only.
Inclusion Criteria:
Subjects meeting diagnostic criteria for MCI:
To ensure that the subject can physically fit in the scanner:
Exclusion Criteria:
Musculoskeletal abnormalities that preclude the ability of the subject to lie on his/her back for 1hr during MRI scanning.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunocal 20gm daily
Dietary Supplement: Immunocal
cysteine-rich whey protein isolate
Change in GSH levels in the brain
Change in cerebral Glutathione levels of MCI patients measured by MRI/MRS scans
Time frame: Baseline compared to month 6 (180 days)
Change in plasma GSH:GSSG ratios measured by HPLC
To evaluate positive correlation between plasma GSH:GSSG ratios and changes in cerebral GSH
Time frame: Baseline compared to month 6 (180 days)
Evaluation of neuropsychological and cognitive functions
The Memory Clinic of JGH Neuropsychological evaluation questionnaire will be used to measure both neuropsychological and cognitive functions
Time frame: Baseline compared to month 6 (180 days)
Plan to share: No
Started Feb 2018 (actual). Primary completion is estimated for Nov 2022, 57 months after the start.
Of 69 industry-sponsored interventional studies with no phase under Cognitive Dysfunction, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 35. This study's planned 57 months is above that.
Counting every sponsor, half of 1,511 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Feb 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Whey Protein Isolate
Immunotec Inc.